{"id":10770,"date":"2019-11-12T10:59:28","date_gmt":"2019-11-12T09:59:28","guid":{"rendered":"https:\/\/udic.es\/?p=10770"},"modified":"2019-11-13T11:05:33","modified_gmt":"2019-11-13T10:05:33","slug":"biogen-will-request-the-approval-to-fda-of-a-new-drug-in-early-alzheimers-disease","status":"publish","type":"post","link":"https:\/\/udic.es\/en\/biogen-will-request-the-approval-to-fda-of-a-new-drug-in-early-alzheimers-disease\/","title":{"rendered":"Biogen will request the approval to FDA of a new drug in early Alzheimer&#8217;s disease."},"content":{"rendered":"<p>&nbsp;<\/p>\n<p class=\"p1\"><span class=\"s1\">On October 22, 2019, Biogen announced the positive result of its EMERGE clinical trial (in which the UDIC has participated) that has evaluated Aducanumab (an anti-alpha synuclein monoclonal antibody) in early Alzheimer&#8217;s disease. Efficacy in slowing cognitive impairment was demonstrated (measured with the CDR-SB, MMSE, ADAS-cog and ADCS-ADL scales) and a reduction in amyloid load detected in PET (almost 80%). The most frequent side effects were cerebral edema (asymptomatic and transient, in general, detected in brain MRI) and headache.These data suport the amyloid hypothesis in this disease and a change in its diagnostic and therapeutic paradigm.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&nbsp; On October 22, 2019, Biogen announced the positive result of its EMERGE clinical trial (in which the UDIC has participated) that has evaluated Aducanumab (an anti-alpha synuclein monoclonal antibody) in early Alzheimer&#8217;s disease. Efficacy in slowing cognitive impairment was demonstrated (measured with the CDR-SB, MMSE, ADAS-cog and ADCS-ADL scales) and a reduction in amyloid&#8230;<\/p>\n","protected":false},"author":2,"featured_media":9457,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[132,135],"tags":[],"class_list":["post-10770","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-alzeimer-en","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.8.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Biogen will request the approval to FDA of a new drug in early Alzheimer&#039;s disease. - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica<\/title>\n<meta name=\"description\" content=\"&nbsp; On October 22, 2019, Biogen announced the positive result of its EMERGE clinical trial (in which the UDIC has participated) that has evaluated\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/udic.es\/en\/biogen-will-request-the-approval-to-fda-of-a-new-drug-in-early-alzheimers-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biogen will request the approval to FDA of a new drug in early Alzheimer&#039;s disease. - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\" \/>\n<meta property=\"og:description\" content=\"&nbsp; On October 22, 2019, Biogen announced the positive result of its EMERGE clinical trial (in which the UDIC has participated) that has evaluated\" \/>\n<meta property=\"og:url\" content=\"https:\/\/udic.es\/en\/biogen-will-request-the-approval-to-fda-of-a-new-drug-in-early-alzheimers-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci%c3%b3-Cl%c3%adnica-447149502490430\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-11-12T09:59:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-11-13T10:05:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/udic.es\/wp-content\/uploads\/2019\/11\/Captura-de-pantalla-2019-11-12-a-las-10.29.24.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1832\" \/>\n\t<meta property=\"og:image:height\" content=\"906\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Tito Surribas\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tito Surribas\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/udic.es\/en\/biogen-will-request-the-approval-to-fda-of-a-new-drug-in-early-alzheimers-disease\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/udic.es\/en\/biogen-will-request-the-approval-to-fda-of-a-new-drug-in-early-alzheimers-disease\/\"},\"author\":{\"name\":\"Tito Surribas\",\"@id\":\"https:\/\/udic.es\/#\/schema\/person\/a8ae8ae960ad58f89663d1d0a2199d1e\"},\"headline\":\"Biogen will request the approval to FDA of a new drug in early Alzheimer&#8217;s disease.\",\"datePublished\":\"2019-11-12T09:59:28+00:00\",\"dateModified\":\"2019-11-13T10:05:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/udic.es\/en\/biogen-will-request-the-approval-to-fda-of-a-new-drug-in-early-alzheimers-disease\/\"},\"wordCount\":110,\"publisher\":{\"@id\":\"https:\/\/udic.es\/#organization\"},\"image\":{\"@id\":\"https:\/\/udic.es\/en\/biogen-will-request-the-approval-to-fda-of-a-new-drug-in-early-alzheimers-disease\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2018\/11\/UDICEQUIPOMEDICO1.jpg\",\"articleSection\":[\"Alzeimer\",\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/udic.es\/en\/biogen-will-request-the-approval-to-fda-of-a-new-drug-in-early-alzheimers-disease\/\",\"url\":\"https:\/\/udic.es\/en\/biogen-will-request-the-approval-to-fda-of-a-new-drug-in-early-alzheimers-disease\/\",\"name\":\"Biogen will request the approval to FDA of a new drug in early Alzheimer's disease. - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\",\"isPartOf\":{\"@id\":\"https:\/\/udic.es\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/udic.es\/en\/biogen-will-request-the-approval-to-fda-of-a-new-drug-in-early-alzheimers-disease\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/udic.es\/en\/biogen-will-request-the-approval-to-fda-of-a-new-drug-in-early-alzheimers-disease\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2018\/11\/UDICEQUIPOMEDICO1.jpg\",\"datePublished\":\"2019-11-12T09:59:28+00:00\",\"dateModified\":\"2019-11-13T10:05:33+00:00\",\"description\":\"&nbsp; On October 22, 2019, Biogen announced the positive result of its EMERGE clinical trial (in which the UDIC has participated) that has evaluated\",\"breadcrumb\":{\"@id\":\"https:\/\/udic.es\/en\/biogen-will-request-the-approval-to-fda-of-a-new-drug-in-early-alzheimers-disease\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/udic.es\/en\/biogen-will-request-the-approval-to-fda-of-a-new-drug-in-early-alzheimers-disease\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/udic.es\/en\/biogen-will-request-the-approval-to-fda-of-a-new-drug-in-early-alzheimers-disease\/#primaryimage\",\"url\":\"https:\/\/udic.es\/wp-content\/uploads\/2018\/11\/UDICEQUIPOMEDICO1.jpg\",\"contentUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2018\/11\/UDICEQUIPOMEDICO1.jpg\",\"width\":1156,\"height\":762,\"caption\":\"UDICEQUIPOMEDICO1\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/udic.es\/en\/biogen-will-request-the-approval-to-fda-of-a-new-drug-in-early-alzheimers-disease\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/udic.es\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biogen will request the approval to FDA of a new drug in early Alzheimer&#8217;s disease.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/udic.es\/#website\",\"url\":\"https:\/\/udic.es\/\",\"name\":\"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\",\"description\":\"Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\",\"publisher\":{\"@id\":\"https:\/\/udic.es\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/udic.es\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/udic.es\/#organization\",\"name\":\"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica\",\"url\":\"https:\/\/udic.es\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/udic.es\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png\",\"contentUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png\",\"width\":408,\"height\":123,\"caption\":\"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica\"},\"image\":{\"@id\":\"https:\/\/udic.es\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci\u00f3-Cl\u00ednica-447149502490430\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/udic.es\/#\/schema\/person\/a8ae8ae960ad58f89663d1d0a2199d1e\",\"name\":\"Tito Surribas\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/udic.es\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ae5f603516ade2643999845ead05442c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ae5f603516ade2643999845ead05442c?s=96&d=mm&r=g\",\"caption\":\"Tito Surribas\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biogen will request the approval to FDA of a new drug in early Alzheimer's disease. - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","description":"&nbsp; On October 22, 2019, Biogen announced the positive result of its EMERGE clinical trial (in which the UDIC has participated) that has evaluated","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/udic.es\/en\/biogen-will-request-the-approval-to-fda-of-a-new-drug-in-early-alzheimers-disease\/","og_locale":"en_US","og_type":"article","og_title":"Biogen will request the approval to FDA of a new drug in early Alzheimer's disease. - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","og_description":"&nbsp; On October 22, 2019, Biogen announced the positive result of its EMERGE clinical trial (in which the UDIC has participated) that has evaluated","og_url":"https:\/\/udic.es\/en\/biogen-will-request-the-approval-to-fda-of-a-new-drug-in-early-alzheimers-disease\/","og_site_name":"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","article_publisher":"https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci%c3%b3-Cl%c3%adnica-447149502490430\/","article_published_time":"2019-11-12T09:59:28+00:00","article_modified_time":"2019-11-13T10:05:33+00:00","og_image":[{"width":1832,"height":906,"url":"https:\/\/udic.es\/wp-content\/uploads\/2019\/11\/Captura-de-pantalla-2019-11-12-a-las-10.29.24.png","type":"image\/png"}],"author":"Tito Surribas","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tito Surribas"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/udic.es\/en\/biogen-will-request-the-approval-to-fda-of-a-new-drug-in-early-alzheimers-disease\/#article","isPartOf":{"@id":"https:\/\/udic.es\/en\/biogen-will-request-the-approval-to-fda-of-a-new-drug-in-early-alzheimers-disease\/"},"author":{"name":"Tito Surribas","@id":"https:\/\/udic.es\/#\/schema\/person\/a8ae8ae960ad58f89663d1d0a2199d1e"},"headline":"Biogen will request the approval to FDA of a new drug in early Alzheimer&#8217;s disease.","datePublished":"2019-11-12T09:59:28+00:00","dateModified":"2019-11-13T10:05:33+00:00","mainEntityOfPage":{"@id":"https:\/\/udic.es\/en\/biogen-will-request-the-approval-to-fda-of-a-new-drug-in-early-alzheimers-disease\/"},"wordCount":110,"publisher":{"@id":"https:\/\/udic.es\/#organization"},"image":{"@id":"https:\/\/udic.es\/en\/biogen-will-request-the-approval-to-fda-of-a-new-drug-in-early-alzheimers-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/udic.es\/wp-content\/uploads\/2018\/11\/UDICEQUIPOMEDICO1.jpg","articleSection":["Alzeimer","News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/udic.es\/en\/biogen-will-request-the-approval-to-fda-of-a-new-drug-in-early-alzheimers-disease\/","url":"https:\/\/udic.es\/en\/biogen-will-request-the-approval-to-fda-of-a-new-drug-in-early-alzheimers-disease\/","name":"Biogen will request the approval to FDA of a new drug in early Alzheimer's disease. - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","isPartOf":{"@id":"https:\/\/udic.es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/udic.es\/en\/biogen-will-request-the-approval-to-fda-of-a-new-drug-in-early-alzheimers-disease\/#primaryimage"},"image":{"@id":"https:\/\/udic.es\/en\/biogen-will-request-the-approval-to-fda-of-a-new-drug-in-early-alzheimers-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/udic.es\/wp-content\/uploads\/2018\/11\/UDICEQUIPOMEDICO1.jpg","datePublished":"2019-11-12T09:59:28+00:00","dateModified":"2019-11-13T10:05:33+00:00","description":"&nbsp; On October 22, 2019, Biogen announced the positive result of its EMERGE clinical trial (in which the UDIC has participated) that has evaluated","breadcrumb":{"@id":"https:\/\/udic.es\/en\/biogen-will-request-the-approval-to-fda-of-a-new-drug-in-early-alzheimers-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/udic.es\/en\/biogen-will-request-the-approval-to-fda-of-a-new-drug-in-early-alzheimers-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/udic.es\/en\/biogen-will-request-the-approval-to-fda-of-a-new-drug-in-early-alzheimers-disease\/#primaryimage","url":"https:\/\/udic.es\/wp-content\/uploads\/2018\/11\/UDICEQUIPOMEDICO1.jpg","contentUrl":"https:\/\/udic.es\/wp-content\/uploads\/2018\/11\/UDICEQUIPOMEDICO1.jpg","width":1156,"height":762,"caption":"UDICEQUIPOMEDICO1"},{"@type":"BreadcrumbList","@id":"https:\/\/udic.es\/en\/biogen-will-request-the-approval-to-fda-of-a-new-drug-in-early-alzheimers-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/udic.es\/en\/"},{"@type":"ListItem","position":2,"name":"Biogen will request the approval to FDA of a new drug in early Alzheimer&#8217;s disease."}]},{"@type":"WebSite","@id":"https:\/\/udic.es\/#website","url":"https:\/\/udic.es\/","name":"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","description":"Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","publisher":{"@id":"https:\/\/udic.es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/udic.es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/udic.es\/#organization","name":"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica","url":"https:\/\/udic.es\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/udic.es\/#\/schema\/logo\/image\/","url":"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png","contentUrl":"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png","width":408,"height":123,"caption":"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica"},"image":{"@id":"https:\/\/udic.es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci\u00f3-Cl\u00ednica-447149502490430\/"]},{"@type":"Person","@id":"https:\/\/udic.es\/#\/schema\/person\/a8ae8ae960ad58f89663d1d0a2199d1e","name":"Tito Surribas","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/udic.es\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ae5f603516ade2643999845ead05442c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ae5f603516ade2643999845ead05442c?s=96&d=mm&r=g","caption":"Tito Surribas"}}]}},"_links":{"self":[{"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/posts\/10770","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/comments?post=10770"}],"version-history":[{"count":0,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/posts\/10770\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/media\/9457"}],"wp:attachment":[{"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/media?parent=10770"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/categories?post=10770"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/tags?post=10770"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}